Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Heritage Family Offices LLP

Heritage Family Offices LLP reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRLFree Report) by 9.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,536 shares of the medical research company’s stock after selling 163 shares during the period. Heritage Family Offices LLP’s holdings in Charles River Laboratories International were worth $284,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in Charles River Laboratories International in the 3rd quarter valued at about $601,000. JPMorgan Chase & Co. lifted its stake in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares in the last quarter. State Street Corp boosted its holdings in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Janus Henderson Group PLC grew its stake in Charles River Laboratories International by 7.6% during the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after purchasing an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $966,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on CRL. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective for the company. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group increased their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $214.00.

Check Out Our Latest Stock Report on CRL

Charles River Laboratories International Stock Down 2.1 %

Charles River Laboratories International stock opened at $174.37 on Thursday. The firm has a market capitalization of $8.92 billion, a P/E ratio of 21.82, a P/E/G ratio of 6.62 and a beta of 1.38. The company has a 50-day simple moving average of $192.56 and a 200-day simple moving average of $198.95. Charles River Laboratories International, Inc. has a one year low of $173.81 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRLGet Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.72 earnings per share. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Company Profile

(Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Recommended Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLFree Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.